ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM stu
ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM study reported at the 2013 Genitourinary Cancers Symposium. Professor Cora Sternberg Chief of Medical Oncology at the San Camillo & Forlanini Hospitals in Rome gave Peter Goodwin more details about why this new generation hormonal therapy is appropriate and how effective it has proved to be in the AFFIRM study in general and among over 75s in particular.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130310CoraSternbergAJOPODCASTLoRes.mp3]
Related Episodes
Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer
ORLANDO—Adjuvant chemotherapy was found to extend life in patients with locally advanced bladder cancer in research reported to the 2015 Genitourinary Cancers Symposium. Matt Galsky MD from the Tisch
Castration-resistant prostate cancer with bone metastases: long follow up shows radium is safe as well as effective
SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasi
Low risk localized prostate cancer: no harm from waiting!
ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Sympo